1. Medtech Insight

DePuy Loses Round One In First Product Liability Trial Involving ASR Metal-On-Metal Hip

A California Superior Court jury agreed with the plaintiff that DePuy's metal-on-metal hip was defective in design, and awarded him $8.3 million in damages. Plaintiff Loren Kransky was the first of 10,700 U.S. litigants slated to be heard in court.

DePuy Orthopaedics Inc. plans to appeal a March 8 jury verdict which found that the DePuyASR XL metal-on-metal hip replacement system was defectively designed, and that plaintiff Loren Kransky should receive more $8.3 million in damages for injuries suffered. Of that amount, $8 million was for physical pain and emotional suffering, and $338,136 was for medical expenses.

The jury rejected Kransky’s claims for punitive damages.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.